Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapse Remitting Multiple Sclerosis”

Showing 20 of 0 results

Large-scale testing (Phase 3)Ended earlyNCT03085810
What this trial is testing

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Hoffmann-La Roche 1,225
Post-approval studies (Phase 4)Study completedNCT02125604
What this trial is testing

Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 214
Large-scale testing (Phase 3)Study completedNCT00459667
What this trial is testing

BEYOND Follow-up: Betaferon®/Betaseron® Efficacy Yielding Outcomes of a New Dose

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 1,420
Large-scale testing (Phase 3)Study completedNCT04121221
What this trial is testing

Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Mapi Pharma Ltd. 1,016
Early research (Phase 1)Study completedNCT01257958
What this trial is testing

Vitamin D Pilot Study in Patients With Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of Wisconsin, Madison
Large-scale testing (Phase 3)Study completedNCT00289978
What this trial is testing

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Novartis 1,272
Not applicableStudy completedNCT00818038
What this trial is testing

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 30
Post-approval studies (Phase 4)Ended earlyNCT00780455
What this trial is testing

Rehabilitation Study in MS Patients

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Bayer 4
Post-approval studies (Phase 4)Study completedNCT02205489
What this trial is testing

Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Genzyme, a Sanofi Company 58
Not applicableStudy completedNCT01541618
What this trial is testing

MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple Sclerosis
MSDx, Inc. 15
Not applicableStudy completedNCT01142518
What this trial is testing

An Observational Study of Multiple Sclerosis (MS) Patients Starting or Restarting Baseline Treatment With Interferon Beta 1a After the Use of Escalation Treatment With Mitoxantrone

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Merck KGaA, Darmstadt, Germany 86
Not applicableStudy completedNCT01485003
What this trial is testing

Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JC Virus Antibody Negative Participants

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 231
Post-approval studies (Phase 4)WithdrawnNCT02675413
What this trial is testing

Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Washington University School of Medicine
Post-approval studies (Phase 4)Active Not RecruitingNCT05296161
What this trial is testing

B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Amsterdam UMC, location VUmc 296
Large-scale testing (Phase 3)Active Not RecruitingNCT05123703
What this trial is testing

Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)

Who this might be right for
Relapsing-remitting Multiple Sclerosis
Hoffmann-La Roche 188
Early research (Phase 1)Study completedNCT01466322
What this trial is testing

Assess the Relative Bioavailability of Different Formulations of GSK2018682, a Sphingosine-1-phosphate Receptor Subtype 1 Agonist, in Healthy Volunteers.

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
GlaxoSmithKline 16
Post-approval studies (Phase 4)Study completedNCT03091569
What this trial is testing

Effects of Vitamin K on Redness Associated With Injection Site Reactions in Participants Treated With Plegridy

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 23
Testing effectiveness (Phase 2)Study completedNCT00640328
What this trial is testing

Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

Who this might be right for
Multiple Sclerosis
GlaxoSmithKline 38
Post-approval studies (Phase 4)Ended earlyNCT02901106
What this trial is testing

Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Fondation Ophtalmologique Adolphe de Rothschild 11
Not applicableUnknownNCT04030819
What this trial is testing

Effectiveness of a Schema Therapy on Anxiety in Patients With Multiple Sclerosis

Who this might be right for
Anxiety
Paris Nanterre University 106
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation